Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, shares details of the randomized Phase III KarMMa-3 trial (NCT03651128), a study investigating idecabtagene vicleucel (ide-cel) in relapsed/refractory (R/R) multiple myeloma. Ide-cel is a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy. In the Phase II KarMMa trial (NCT03361748), ide-cel was shown to induce deep responses in heavily pretreated myeloma patients. This study will compare ide-cel to standard regimens in patients with 2-4 prior lines of therapy. The target dose level will be 450 × 106 CAR+ T-cells, the most efficacious dose in previous trials. Progression-free survival will be examined as the primary endpoint, with overall response rate, measurable residual disease, response duration, immunogenicity and biomarkers also being explored. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Michel Delforge, MD, PhD, has participated in advisory boards for Amgen, Celgene-BMS, GSK, Janssen, Takeda and Sanofi; and has received research grants from Amgen, Celgene, Janssen, Takeda and Sanofi.